ANVS
Annovis Bio, Inc.
Next earnings Aug 10, 2026 · consensus $-0.47 EPS
Last earnings -3.3% on 2026-05-15
$1.72
▲ +4.24%$1.72▼ -34.85%
over 1Y
L $1.59EODHDH $5.10
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.2%
1W-2.8%
1M-14.4%
3M-15.3%
YTD-52.9%
1Y-34.8%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Conservative balance sheet (liabilities/equity 0.25x).
Revenue (FY2025) $0.00 · FY2025
Annovis Bio, Inc. shows $0.00 in FY2025 revenue, and -171.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$14.5M | -$25.5M | -$45.0M | -$26.7M | -$29.7M |
| Net income | -$14.5M | -$25.3M | -$56.2M | -$24.6M | -$28.9M |
| Diluted EPS | -$1.90 | -$3.10 | -$6.23 | -$2.31 | -$1.40 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$29.2M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-59.2%
FCF yield—
Quality & risk
ROIC (est.)-139.2%
Free cash flow—
Total debt—
Net cash$19.5M
Altman Z-Score-8.23 distress
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+45.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-172026-06-17open ↗4Period ending 2026-05-202026-05-21open ↗8-KPeriod ending 2026-05-202026-05-20open ↗424B5Filing2026-05-20open ↗424B5Filing2026-05-19open ↗10-QPeriod ending 2026-03-312026-05-15open ↗8-KPeriod ending 2026-05-152026-05-15open ↗DEFA14AFiling2026-04-30open ↗DEF 14APeriod ending 2026-06-172026-04-30open ↗8-KPeriod ending 2026-04-092026-04-10open ↗424B5Filing2026-04-09open ↗4Period ending 2026-04-022026-04-03open ↗
Frequently asked
- Is Annovis Bio, Inc. (ANVS) a buy?
- ANVS currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.25x).
- What is Annovis Bio, Inc.'s quality score?
- ANVS scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001477845, latest 10-Q filed 2026-05-15) · EODHD · as of 6/26/2026, 6:14:39 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.